Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Seon-Kyu Kim

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

S. Kim1, J. Park2, H. Kim2, J. Kim1, S. Kim1, S. Lee3, K. Song4, W. Kim5, Y.S. Kim2

Author affiliations

  • 1 Personalized Genomic Medicine Research Center, KRIBB-Korea Research Institute of Bioscience and Biotechnology, 34141 - Daejeon/KR
  • 2 Genome Editing Research Center, KRIBB-Korea Research Institute of Bioscience and Biotechnology, 34141 - Daejeon/KR
  • 3 Department Of General Surgery, Chungnam National University, College of Medicine, 35015 - Daejeon/KR
  • 4 Department Of Pathology, Chungnam National University, College of Medicine, 35015 - Daejeon/KR
  • 5 Department Of Pathology, Seoul National University, Faculty of Medicine, 03080 - Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1413

Background

Although recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for handling diffuse type GC are identified. Here, we aim to identify a prognostic and predictive signature predicting heterogeneous clinical courses of diffuse type GC.

Methods

We analysed RNA-seq based transcriptome data to identify a molecular signature in 150 gastric tissue samples including 107 diffuse type GCs. The predictive value of the signature was verified using other diffuse type GCs in three independent cohorts (n = 466). Various statistical methods, including log-rank and Cox regression analyses, were used to estimate an association between the signature and prognosis. The signature was also characterized by somatic variant assessments and tissue microarray analysis between diffuse type GC subtypes.

Results

Transcriptomic profiling revealed two distinct subtypes of diffuse type GC including intestinal-like (INT) and core diffuse type (COD) subgroups. We generated a signature, namely COD-signature, reflecting the best characteristics of subtypes. When estimating prognostic value in other cohorts, COD-signature showed a strong predictability and an independent clinical utility in diffuse type GC prognosis (hazard ratio = 2.058, 95% confidence interval = 1.53-2.77, P < 0.001; Table). Integrative mutation and gene expression analyses demonstrated that COD subtype was responsive to chemotherapy, whereas INT subtype showed responsiveness to immunotherapy with immune-check point inhibitor (ICI). Tissue microarray analysis showed practical utility of IGF1 and NXPE2 proteins for predicting diffuse type GC’s heterogeneity.Table: 155P

Univariate and multivariate Cox regression analysis of overall survival in diffuse type gastric cancer

VariablesUnivariateMultivariate
nHR (95% CI)P-valuenHR (95% CI)P-value
Age4021.013 (1.001 - 1.025)0.0374021.02 (1.007 - 1.032)0.003
Gender (Male or Female)4021.074 (0.805 - 1.433)0.625
AJCC Stage (I, II, III or IV)4022.516 (2.088 - 3.032)<0.0012.67 (2.204 - 3.235)<0.001
Tumour site (cardia, body, antrum or whole)4020.985 (0.777 - 1.248)0.9
COD-signature (INT or COD subtypes)4021.675 (1.257 - 2.234)<0.0012.058 (1.53 - 2.766)<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; INT, intestinal-like; COD, core diffuse type.

Conclusions

The COD-signature represents a promising diagnostic tool for the identification of diffuse type GC patients who would display different clinical behaviours as well as response to chemotherapy or ICI treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Korea Research Institute of Bioscience and Biotechnology Chungnam National University, College of Medicine Seoul National University, Faculty of Medicine.

Funding

Korea Research Institute of Bioscience and Biotechnology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.